4 reports of this reaction
1.5% of all AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE reports
#17 most reported adverse reaction
BREAST CANCER is the #17 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, manufactured by Kenvue Brands LLC. There are 4 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE to BREAST CANCER. This represents approximately 1.5% of all 273 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE who experience breast cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER is a less commonly reported adverse event for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, but still significant enough to appear in the safety profile.
In addition to breast cancer, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE:
The following drugs have also been linked to breast cancer in FDA adverse event reports:
BREAST CANCER has been reported as an adverse event in 4 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER accounts for approximately 1.5% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, making it a notable side effect.
If you experience breast cancer while taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.